

Name	Yung-Luen Yu (余永倫)
Contact Information	
Office Address	9F, No.6, Hsueh-Shih Road, Graduate Institute of Cancer Biology, China Medical University, Taichung 404, Taiwan
E-mail	ylyu@mail.cmu.edu.tw
Current Positions	Dean, Graduate Student Affairs, China Medical University Professor, Graduate Institute of Biomedical Sciences, China Medical University Research Fellow, Center for Molecular Medicine, China Medical University Hospital
Education	B.S., Department of Horticulture, Chinese Culture University (1988-1992) M.S., Graduate Institute of Life Sciences, National Tsing Hua University (1993-1995) Ph.D., Graduate Institute of Life Sciences, National Defense Medical Center (1996-2002)
Professional Experiences	Postdoctoral fellow: Institute of Biomedical Sciences, Academia Sinica (2002-2004) Postdoctoral fellow: Department of Molecular and Cellular Oncology , University Texas M. D. Anderson Cancer Center (2005-2007) Assistant Professor: Graduate Institute of Cancer Biology, China Medical University (2007.01-2011.01) Associate Professor: Graduate Institute of Cancer Biology, China Medical University (2011.02-2015.07) Research Fellow: Center for Molecular Medicine, China Medical University Hospital (2011.04-) Professor: Graduate Institute of Cancer Biology, China Medical University (2015.08- 2016.07) Director: Graduate Institute of Cancer Biology, China Medical University (2011.02- 2016.07) Professor: Graduate Institute of Biomedical Sciences, China Medical University (2016.08-) Dean: Graduate Student Affairs, China Medical University (2017.02-)

SOCIETY MEMBERSHIPS

Phi Tau Phi Scholastic Honor Society (1993-present)

American Association for Cancer Research (2010-present)

Reviewer for:

Journal of Agricultural and Food Chemistry (2010, 2013)

Cell Biochemistry and Biophysics (2012)

Herald Journal of Pharmacy and Pharmacological Research (2012)

BioMed Research International (2013)

Adaptive Medicine (2013, 2014)

PLoS ONE (2013-2016)

International Journal of Nanomedicine (2013, 2014)

Neuroscience (2014)

Journal of Gastroenterology and Hepatology (2014)

Drug Design, Development and Therapy (2014)

ACS Applied Materials & Interfaces (2014)

Tumor Biology (2015, 2016, 2017)

Oncotarget (2015, 2016, 2017)

Oncogene (2015, 2016)

Scientific Report (2016, 2017)

International Journal of Cancer (2016)

Honors:

Distinguished Teaching Professor, College of Medicine, China Medical University (2007)

Distinguished Teaching Professor, College of Medicine, China Medical University (2009)

PUBLICATIONS: Yung-Luen Yu (*Correspondence; †Co-first author)

1. Chen W[†], **Yu YL[†]**, Lee SF, Chiang YJ, Chao JR, Huang JH, Chiong JH, Huang CJ, Lai MZ, Yang-Yen HF, and Yen JY*. CREB is one component of the binding complex of the Ces-2/E2A-HLF binding element and is an integral part of the interleukin-3 survival signal. *Mol Cell Biol.* **2001** 21: 4636-46.
2. **Yu YL**, Chiang YJ, and Yen JY. GATA *factors are essential for transcription of the survival gene *E4bp4* and the viability response of interleukin-3 in Ba/F3 hematopoietic cells. *J Biol Chem.* **2002** 277: 27144-53.
3. **Yu YL**, Chiang YJ, Chen YC, Papetti M, Juo CG, Skoultchi AI, and Yen JY*. MAP kinase-mediated phosphorylation of GATA-1 promotes *Bcl-X_L* expression and cell survival. *J Biol Chem.* **2005** 280: 29533-42.
4. Wang SC[†], Nakajima Y[†], **Yu YL[†]**, Xia W, Chen CT, Yang CC, McIntush EW, Li LY, Hawke DH, Kobayashi R, and Hung MC*. Tyrosine phosphorylation controls PCNA function through protein stability. *Nat Cell Bio.* **2006** 8(12): 1359-1368.
5. Yiang GT[†], **Yu YL[†]**, Hu SC, Chen MHC, Wang JJ, and Wei CW*. PKC and MEK pathways inhibit caspase-9/-3-mediated cytotoxicity in differentiated cells. *FEBS Letters.* **2008** 582(6): 881-885.
6. Lin PC, Chen YL, Chiu SC, **Yu YL**, Chen SP, Chien MH, Chen KY, Lin SZ, Chiou TW, and Harn HJ*. Orphan nuclear receptor, Nurr-77 was a possible target gene of butylidenephthalide chemotherapy on glioblastoma multiform brain tumor. *J Neurochem.* **2008** 106(3): 1017-1026.

7. Yiang GT[†], Harn HJ[†], **Yu YL[†]**, Hu SC, Hung YT, Hsieh CJ, Lin SZ and Wei CW*. Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice. *J Biomed Sci.* **2009** 16:47.
8. Xia W, Wei Y, Du Y, Liu J, Chang B, **Yu YL**, Huo LF, Miller S, and Hung MC*. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. *Mol Carcinog.* **2009** 48 (7): 610-617.
9. Wei CW[†], Lin CC[†], **Yu YL[†]**, Lin CY, Lin PC, Wu MT, Chen CJ, Chang W, Lin SZ, Chen YL, and Harn HJ*. n-Butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2alpha and telomerase activity. *Acta Pharmacol Sin.* **2009** 30(9):1297-306.
10. **Yu YL[†]**, Wei CW[†], Chen YL, Chen MHC, and Yiang GT*. Immunotherapy of breast cancer by single delivery with rAAV2-mediated interleukin-15 expression. *Int J Oncol.* **2010** 36(2): 365-370.
11. **Yu YL[†]**, Yu SL[†], Su KJ, Wei CW, Jian MH, Lin PC, Tseng IH, Lin CC, Su CC, Chan DC, Lin SZ, Harn HJ, and Chen YL*. Extended MGMT promoter hypermethylation following n-Butylidenephthalide combined with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on inhibition of HCC carcinoma cells growth. *J Agric Food Chem.* **2010** 58, 1630-1638.
12. Huo L, Wang YN, Xia W, Hsu SC, Lai CC, Li LY, Chang WC, Wang Y, Hsu MC, **Yu YL**, Huang TH, Ding Q, Chen CH, Tsai CH, and Hung MC*. RNA helicase A is a DNA-binding partner for EGFR mediated transcriptional activation in the nucleus. *Proc Natl Acad Sci U S A.* **2010** 107(37), 16125-16130.
13. Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, **Yu YL**, Lan CC, Yang CH, Lin SB, Wu CP, Shih JY, Yang PC*. Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. *Am J Respir Crit Care Med.* 15;183(8):1071-1079, **2011**.
14. Yu SL[†], Lin SB[†], **Yu YL[†]**, Chien MH, Su KJ, Lin CJ, Way TD, Yiang GT, Lin CC, Chan DC, Harn HJ, Chen YL*. Isochaihulactone protects PC12 cell against H(2)O(2) induced oxidative stress and exerts the potent anti-aging effects in D-galactose aging mouse model. *Acta Pharmacol Sin.* **2010** 31(12):1532-1540.
15. Tseng HH[†], **Yu YL[†]**, Chen YL, Chen JH, Chou CL, Kuo TY, Wang JJ, Lee MC, Huang TH, Chen MH, Yiang GT*. RC-RNase-induced cell death in estrogen receptor positive breast tumors through down-regulation of Bcl-2 and estrogen receptor. *Oncol Rep.* **2011** 25(3):849-853.
16. **Yu YL*[†]**, Chou RH[†], Chen LT, Shyu WC, Hsieh SC, Wu CS, Zeng HJ, Yeh SP, Yang DM, Hung SC, Hung MC*. EZH2 Regulates Neuronal Differentiation of Mesenchymal Stem Cells through PIP5K1C-dependent Calcium Signaling. *J Biol Chem.* **2011** 286(11):9657-9667.
17. **Yu YL*[†]**, Su KJ[†], Chen CJ, Wei CW, Lin CJ, Yiang GT, Lin SZ, Harn HJ, Chen YL*. Synergistic anti-tumor activity of isochaihulactone and paclitaxel on human lung cancer cells. *J Cell Physiol.* **2012** 227:213-222.
18. Chou RH, **Yu YL***, Hung MC*. The roles of EZH2 in cell lineage commitment. *Am J Transl Res.* **2011** 3(3):243-250.
19. Yiang GT, Chou PL, Tsai HF, Chen LA, Chang WJ, **Yu YL***, Wei CW*. Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice. *Int J Mol Med.* **2012** 29: 809-814.
20. Lai TW, Lin SZ, Lee HT, Fan JR, Hsu YH, Wang HJ, **Yu YL**, Shyu WC*. HIF-1 α binding to the Epac1 promoter recruits hematopoietic stem cells to the ischemic brain following stroke. *J Mol Cell Biol.* **2012** 4(3):184-187.
21. Yiang GT[†], **Yu YL[†]**, Chou PL, Tsai HF, Chen LA, Chen YH, Su KJ, Wang JJ, Bau DT, Wei CW*. The Cytotoxic Protein Can Induce Autophagocytosis in Addition to Apoptosis in MCF-7 Human Breast Cancer Cells. *In Vivo.* **2012** 26(3):403-409.
22. Wu CS, Yen CJ, Chou RH, Li ST, Huang WC, Ren CT, Wu CY*, **Yu YL***. Cancer-associated carbohydrate antigens as potential biomarkers for hepatocellular carcinoma. *PLoS One.* **2012** 7(7):e39466. Epub Jul 13.
23. **Yu YL*[†]**, Chou RH[†], Wu CH, Wang YN, Chang WJ, Tseng YJ, Chang WC, Lai CC, Lee HJ, Huo L, Chen CH, Hung MC*. Nuclear EGFR Suppresses Ribonuclease Activity of Polynucleotide Phosphorylase through DNAPK-mediated Phosphorylation at Serine 776. *J Biol Chem.* **2012** 287(37):31015-31026.

24. Yang YC, Lin HY, Su KY, Chen CH, **Yu YL**, Lin CC, Yu SL, Yan HY, Su KJ, Chen YL*. Rutin, a Flavonoid That Is a Main Component of *Saussurea involucrata*, Attenuates the Senescence Effect in D-Galactose Aging Mouse Model. *Evid Based Complement Alternat Med*. Epub **2012** Aug 16.
25. Chiou SH, Jiang BH^{††}, **Yu YL**^{††}, Chou SJ, Tsai PH, Chang WC, Chen LK, Chen LH, Chien Y, Chiou GY. Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc. *J Exp Med*. **2013** Jan 14; 210(1):85-98. (^{††}co-second author)
26. Yiang GT, Chen YH, Chou PL, Chang WJ, Wei CW*, **Yu YL***. The NS3 protease and helicase domains of Japanese encephalitis virus trigger cell death via caspase-dependent and -independent pathways. *Mol Med Rep*. **2013** Mar; 7(3):826-30.
27. Hsia TC, Tu CY, Chen YJ, Wei YL, Yu MC, Hsu SC, Tsai SL, Chen WS, Yeh MH, Yen CJ, **Yu YL**, Huang TC, Huang CY, Hung MC, Huang WC*. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. *Mol Pharmacol*. **2013** Apr; 83(4):857-69.
28. **Yu YL***[†], Chou RH[†], Shyu WC[†], Hsieh SC, Wu CS, Chiang SY, Chang WJ, Chen JN, Tseng YJ, Lin YH, Lee W, Yeh SP, Hsu JL, Yang CC, Hung SC, Hung MC*. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. *EMBO Mol Med*. **2013** Apr; 5(4):531-47.
29. **Yu YL***, Chou RH, Liang JH, Chang WJ, Su KJ, Tseng YJ, Huang WC, Wang SC, Hung MC*. Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides. *PLoS One*. **2013** Apr 8; 8(4):e61362.
30. Lin CH, Lee HT, Lee SD, Lee W, Cho CW, Lin SZ, Wang HJ, Okano H, Su CY, **Yu YL**, Hsu CY, Shyu WC*. Role of HIF-1 α -activated Epac1 on HSC-mediated neuroplasticity in stroke model. *Neurobiol Dis*. **2013** Oct;58:76-91.
31. Chiang TY[†], **Yu YL**[†], Lin CW, Tsao SM, Yang SF, Yeh CB*. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia. *Clin Chim Acta*. **2013** Sep 23, 424: 261-6.
32. Lee SD, Lai TW, Lin SZ, Lin CH, Hsu YH, Li CY, Wang HJ, Lee W, Su CY, **Yu YL***, Shyu WC*. Role of stress-inducible protein-1 in recruitment of bone marrow derived cells into the ischemic brains. *EMBO Mol Med*. **2013** Aug; 5(8): 1227-46.
33. Chen YJ, Chien PH, Chen WS, Chien YF, Hsu YY, Wang LY, Chen JY, Lin CW, Huang TC, **Yu YL**, Huang WC* Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma Cells. *Evid Based Complement Alternat Med*.; **2013** Jun 11; 682380. doi: 10.1155/2013/682380. Epub.
34. Chou RH, Hsieh SC, **Yu YL**, Huang MH, Huang YC, Hsieh YH*. Fisetin Inhibits Migration and Invasion of Human Cervical Cancer Cells by Down-Regulating Urokinase Plasminogen Activator Expression through Suppressing the p38 MAPK-Dependent NF- κ B Signaling Pathway. *PLoS One*. **2013** Aug 5;8(8):e71983. doi: 10.1371/journal.pone.0071983.
35. **Yu YL**[†], Su KJ[†], Hsieh YH, Lee HL, Chen TY, Hsiao PC, Yang SF*. Effects of EZH2 Polymorphisms on Susceptibility to and Pathological Development of Hepatocellular Carcinoma. *PLoS One*. **2013** Sep 10;8(9):e74870. doi: 10.1371/journal.pone.0074870.
36. Chang SL, Chou RH, Zeng HJ, Lin YH, Chiu TY, Yang DM, Hung SC, Lai CH, Hsieh JT, Shyu WC*, **Yu YL***. Downregulation of DAB2IP Promotes Mesenchymal-To-Neuroepithelial Transition and Neuronal Differentiation of Human Mesenchymal Stem Cells. *PLoS One*. **2013** Sep 20;8(9):e75884. doi: 10.1371/journal.pone.0075884.
37. Wu CS, Yen CJ, Chou RH, Chen JN, Huang WC, Wu CY*, **Yu YL***. Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression. *Int J Cancer*. **2014** Apr 1;134(7):1638-47.
38. Chen YJ, Yeh MH, Yu MC, Wei YL, Chen WS, Chen JY, Shih CY, Tu CY, Chen CH, Hsia TC, Chien PH, Liu SH, **Yu YL**, Huang WC*. Lapatinib--induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. *Breast Cancer Res*. **2013** Nov 12;15(6):R108.
39. Chiou GY[†], Chien CS[†], Wang ML[†], Chen MT[†], Yang YP[†], **Yu YL**[†], Chien Y, Chang YC, Shen CC, Chio CC, Lu KH, Ma HI, Chen KH, Liu DM, Miller SA, Chen YW, Huang PI, Shih YH, Hung MC*, Chiou SH*. Epigenetic Regulation of the miR142-3p/Interleukin-6 Circuit in Glioblastoma. *Mol Cell*. **2013** Dec 12; 52(5): 679-692.

40. Ko CP[†], **Yu YL[†]**, Hsiao PC, Yang SF, Yeh CB*. Plasma levels of soluble Axl correlate with severity of community-acquired pneumonia. *Mol Med Rep.* **2014** Apr 9(4):1400-4.
41. Yiang GT, Tsai HF, Chen JR, Chou PL, Wu TK, Liu HC, Chang WJ, Liu LC, Tseng HH*, **Yu YL***. RC-6 ribonuclease induces caspase activation, cellular senescence and neuron-like morphology in NT2 embryonal carcinoma cells. *Oncol Rep.* **2014** Apr;31(4):1738-44.
42. Yiang GT, Chou RH, Chang WJ, Wei CW*, **Yu YL***. Long-term expression of rAAV2-hIL15 enhances immunoglobulin production and lymphokine-activated killer cell-mediated human glioblastoma cell death. *Mol Clin Oncol.* **2013** Mar;1(2):321-325.
43. **Yu YL[†]**, Yiang GT[†], Chou PL, Tseng HH, Wu TK, Hung YT, Lin PS, Lin SY, Liu HC, Chang WJ, Wei CW*. Dual role of acetaminophen in promoting hepatoma cell apoptosis and kidney fibroblast proliferation. *Mol Med Rep.* **2014** Jun;9(6):2077-84.
44. **Yu YL[†]**, Su KJ[†], Hsieh MJ, Wang SS, Wang PH, Weng WC, Yang SF*. Impact of EZH2 Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathologic Features. *PLoS One.* **2014** Apr 1;9(4):e93635. doi: 10.1371/journal.pone.0093635. eCollection.
45. Chang LC, Lin HY, Tsai MT, Chou RH, Lee FY, Teng CM, Hsieh MT, Hung HY, Huang LJ, **Yu YL***, Kuo SC*. YC-1 inhibits proliferation of breast cancer cells by downregulating EZH2 expression via activation of c-Cbl and ERK. *Br J Pharmacol.* **2014** Sep;171(17):4010-25.
46. Chou RH, Lu CY; Wei-Lee, Fan JR, **Yu YL***, Shyu WC*. The potential therapeutic applications of olfactory ensheathing cells in regenerative medicine. *Cell Transplant.* **2014**;23(4-5):567-71.
47. Yeh CB, **Yu YL[†]**, Lin CW, Chiou HL, Hsieh MJ, Yang SF*. Terminalia catappa attenuates urokinase-type plasminogen activator expression through Erk pathways in Hepatocellular carcinoma. *BMC Complement Altern Med.* **2014** Apr 30;14:141.
48. Wu CS, Lee TY, Chou RH, Yen CJ, Huang WC, Wu CY, **Yu YL***. Development of a Highly Sensitive Glycan Microarray for Quantifying AFP-L3 for Early Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma. *PLoS One.* **2014** Jun 13;9(6):e99959.
49. Yiang GT, Chou PL, Hung YT, Chen JN, Chang WJ, **Yu YL***, Wei CW*. Vitamin C enhances anticancer activity in methotrexate-treated Hep3B hepatocellular carcinoma cells. *Oncol Rep.* **2014** Sep;32(3):1057-63.
50. Lai CH*, Chang CS, Liu HH, Tsai YS, Hsu FM, **Yu YL**, Lai CK, Gandee L, Pong RC, Hsu HW, Yu L, Saha D, Hsieh JT*. Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. *Oncotarget.* **2014** Jul 30;5(14):5523-34.
51. Chou RH, Wang YN, Hsieh YH, Li LY, Xia W, Chang WC, Chang LC, Cheng CC, Lai CC, Hsu J L, Chang WJ, Chiang SY, Lee HJ, Liao HW, Chuang PH, Chen HY, Kuo SC, Chen CH, **Yu YL*** and Hung MC*. EGFR modulates DNA synthesis and repairs through Tyr phosphorylation of Histone H4. *Dev Cell* **2014** Jul 28;30(2):224-237.
52. Chou RH, Chiu L, **Yu YL***, Shyu WC*. The Potential Roles of EZH2 in Regenerative Medicine. *Cell Transplant.* **2015** Feb 2. [Epub ahead of print]
53. Chang LC, **Yu YL[†]**, Liu CY, Cheng YY, Chou RH, Hsieh MT, Lin HY, Hung HY, Huang LJ, Wu YC, Kuo SC. The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1. *Cancer Chemother Pharmacol.* **2015 Jun**;75(6):1303-15. doi: 10.1007/s00280-015-2765-0. Epub 2015 May
54. Chen JN, Yiang GT, Lin YF, Chou PL, Wu TK, Chang WJ, Chen C, **Yu YL***. *Rana catesbeiana* ribonuclease induces cell apoptosis via the caspase-9/-3 signaling pathway in human glioblastoma DBTRG, GBM8901 and GBM8401 cell lines. *Oncol Lett.* **2015 Jun**;9(6):2471-2476. Epub 2015 Apr 15.
55. Yiang GT, Chen JN, Wu TK, Wang HF, Hung YT, Chang WJ, Chen C, Wei CW, **Yu YL***. Ascorbic acid inhibits TPA-induced HL-60 cell differentiation by decreasing cellular H2O2 and ERK phosphorylation. *Mol Med Rep.* **2015 Oct**;12(4):5501-7
56. Wu TK, Wei CW, Pan YR, Cherng SH, Chang WJ, Wang HF, **Yu YL***. Vitamin C attenuates the toxic effect of aristolochic acid on renal tubular cells via decreasing oxidative stress-mediated cell death pathways. *Mol Med Rep.* **2015 Aug 3**. doi: 10.3892/mmr.2015.4167. [Epub ahead of print]

57. Yiang GT, **Yu YL** †, Lin KT, Chen JN, Chang WJ, Wei CW. Acetaminophen induces JNK/p38 signaling and activates the caspase-9-3-dependent cell death pathway in human mesenchymal stem cells. *Int J Mol Med*. **2015** Aug;36(2):485-92.
58. Su KJ, Ho CC, Lin CW, Chen MK, Su SC, **Yu YL***, Yang SF*. Combinations of FUT2 gene polymorphisms and environmental factors are associated with oral cancer risk. *Tumour Biol*. **2016** May;37(5):6647-52
59. Su KJ, Lin CW, Chen MK, Yang SF, **Yu YL***, Effects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology. *Am J Cancer Res*. **2015** Oct 15;5(11):3475-84.
60. Chang LC, **Yu YL***. Dietary components as epigenetic-regulating agents against cancer. *Biomedicine (Taipei)*. **2016** Mar;6(1):2. doi:
61. Chang LC, **Yu YL** †, Hsieh MT, Wang SH, Chou RH, Huang WC, Lin HY, Hung HY, Huang LJ, Kuo SC. A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics. *Am J Cancer Res*. **2016** Mar 15;6(4):747-63.
62. Yeh YW, Cheng CC, Yang ST, Tseng CF, Chang TY, Tsai SY, Fu E, Chiang CP, Liao LC, Tsai PW, **Yu YL***, Su JL*. Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling. *Oncotarget*. **2017** Jan 17;8(3):5603-5618.
63. Tsai YL, Hua KF, Chen A, Wei CW, Chen WS, Wu CY, Chu CL, Yu YL, Lo CW, Ka SM. NLRP3 inflammasome: Pathogenic role and potential therapeutic target for IgA nephropathy. *Sci Rep*. **2017** Jan 24;7:41123.
64. Wu CW, Liu HC, Yu YL, Hung YT, Wei CW, Yiang GT. Combined treatment with vitamin C and methotrexate inhibits triple-negative breast cancer cell growth by increasing H2O2 accumulation and activating caspase-3 and p38 pathways. *Oncol Rep*. **2017** Apr;37(4):2177-2184.
65. Chen CT, Liao WY, Hsu CC, Hsueh KC, Yang SF, Teng YH, Yu YL. *FUT2* genetic variants as predictors of tumor development with hepatocellular carcinoma. *Int J Med Sci*. **2017** Jul 19;14(9):885-890.
66. Chiou J, Su CY, Jan YH, Yang CJ, Huang MS, Yu YL, Hsiao M. Decrease of FSTL1-BMP4-Smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma. *Sci Rep*. **2017** Aug 29;7(1):9830.